Eosinophilia-Myalgia Syndrome-New Mexico
JAMA 262:3116, Belvins,W.L.,et al, 1989
Drug Reaction with Eosinophilia and Systemic Symptoms after Daclizamub Therapy
Neurol 91:e359-e363, Rauer,S.,et al, 2018
Clinical Reasoning: A 28-year-old IV Drug User with Bilateral Basal Ganglia and Brainstem Lesions
Neurol 80:e73-e76, Lin, T.,et al, 2013
Movement Disorders Emergencies Part 1
, Robottom, B.J., et al, 2011
The Clinical and Radiological Spectrum of Reversible Cerebral Vasoconstriction Syndrome. A Prospective Series of 67 Patients
Brain 130:3091-3101, Ducros, A.,et al, 2007
The Serotonin Syndrome
NEMJ 352:1112-20, Boyer, E.W. & Shannon, M., 2005
Vasculitic Mononeuritis Multiplex Induced by Valcyclovir
Neurol 62:1906-1907, Pary,L.F.,et al, 2004
Clomipramine Induced Neuroleptic Malignant Syndrome and Pyrexia of Unknown Origin
BMJ 329:1333-1335, Haddow,A.M.,et al, 2004
Serotonin Sydrome
Medicine 79:201-209, Mason,P.J. et al, 2000
Acute, Drug-Induced, Life-Threatening Neurological Syndromes
The Neurologist 4:196-210, Richard,I.H., 1998
Oral and Genital Tardive Pain Syndromes
Neurol 44:2115-2119, Ford,B.,et al, 1994
Neurotoxicity After Treatment with Muromonab-CD3
NEJM 323:487-488, Richards,J.M.,et al, 1990
Nicotinic Acid-Associated Myopathy:A Report of Three Cases
Am J Med 86:481-483, Litin,S.C.&Snderson,C.G., 1989
Neuroleptic Malignant Syndrome, Review of Response to Therapy
Arch Int Med 149:1927-1931, Rosenberg,M.R.&Green,M., 1989
Dopamine Agonists, In Parkinson's Disease and Movement Disorders
Urban & Schwarzenberg, Balt, p. 104., Jankovic,J.&Tolosa,E., 1988
The Neuroleptic Malignant Syndrome
Arch Int Med 142:1183-1185, Smego,R.A.,et al, 1982
Neuroleptic Malignant Syndrome
Arch Neurol 37:462-463, Morris,H.H.,et al, 1980
Anticholinergics
NEJM 288:1215, Greenblatt,D.J.,et al, 1973